Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RICKEY D MANNING

Allopathic & Osteopathic Physicians Family Medicine

NPI
1831126812
CMS profile
219193
Location
KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$8,817.82

82 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $7,896.25 5
Food and Beverage $921.57 77

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $7,994.23 11
ABBVIE INC. $298.50 33
Novo Nordisk Inc $258.96 18
GlaxoSmithKline, LLC. $144.51 12
Abbott Laboratories $53.19 4
Inspire Medical Systems, Inc. $27.90 1
SANOFI PASTEUR INC. $13.85 1
E.R. Squibb & Sons, L.L.C. $13.51 1
Antares Pharma, Inc. $13.17 1

Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RICKEY D MANNING

NPI 1831126812 · CMS profile ID 219193

Allopathic & Osteopathic Physicians / Family Medicine

KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1831126812?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RICKEY D MANNING, NPI 1831126812, CMS profile ID 219193. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1831126812?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RICKEY D MANNING, NPI 1831126812, CMS profile ID 219193. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1831126812?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RICKEY D MANNING, NPI 1831126812, CMS profile ID 219193, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1831126812?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

82 matching records · $8,817.82 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 82 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–82 of 82.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $13.4105/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997834667 CMS
GlaxoSmithKline, LLC. $2.1604/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003193969 CMS
ABBVIE INC. $18.5504/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997834665 CMS
ABBVIE INC. $9.2204/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997834663 CMS
Novo Nordisk Inc $10.2604/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001676733 CMS
ABBVIE INC. $2.7004/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997834661 CMS
GlaxoSmithKline, LLC. $15.5904/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003192077 CMS
Novo Nordisk Inc $13.5604/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001676789 CMS
ABBVIE INC. $5.7104/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997834659 CMS
Abbott Laboratories $13.8804/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018664949 CMS
PFIZER INC. $15.0803/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050402519 CMS
GlaxoSmithKline, LLC. $16.7903/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003192061 CMS
ABBVIE INC. $2.3403/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997834657 CMS
Novo Nordisk Inc $11.9703/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001676742 CMS
PFIZER INC. $16.7003/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050516175 CMS
ABBVIE INC. $8.8103/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997834655 CMS
PFIZER INC. $3,596.2503/06/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050615677 CMS
Novo Nordisk Inc $22.3803/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001676839 CMS
ABBVIE INC. $14.9003/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997834653 CMS
GlaxoSmithKline, LLC. $11.4002/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003194025 CMS
PFIZER INC. $3,000.0002/20/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049269398 CMS
PFIZER INC. $400.0002/20/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049350449 CMS
Antares Pharma, Inc. $13.1702/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054600215 CMS
Novo Nordisk Inc $23.4602/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001676849 CMS
ABBVIE INC. $14.6902/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997834649 CMS
ABBVIE INC. $9.9302/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997834651 CMS
PFIZER INC. $400.0001/30/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050648309 CMS
ABBVIE INC. $4.3301/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997834647 CMS
PFIZER INC. $13.9601/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049441199 CMS
ABBVIE INC. $8.2201/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997834645 CMS
Novo Nordisk Inc $7.5201/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001676703 CMS
GlaxoSmithKline, LLC. $19.7301/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003195087 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $578.76 34
PY2020 $254.84 17
PY2021 $957.35 61
PY2022 $828.45 69
PY2023 $8,817.82 82
PY2024 $1,310.02 98
PY2025 $1,513.54 103

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,231,346.77 295
PY2024 Principal investigator $1,244,354.71 90
PY2023 Principal investigator $1,942,596.18 687
PY2022 Principal investigator $1,313,483.85 338
PY2021 Recipient $65.13 1
PY2021 Principal investigator $566,162.00 82
PY2020 Principal investigator $304,525.65 85
PY2019 Recipient $2,685.50 29
PY2019 Principal investigator $470,736.54 81

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

295 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202532905
Principal investigator 1 Genentech, Inc. $8,426.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568854
Principal investigator 1 GlaxoSmithKline, LLC. $1,651.10 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192181766
Principal investigator 1 Hoffmann-La Roche Limited $7,582.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,520.85 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184278882
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,007.18 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184278894
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,849.50 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184278896
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $855.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184278898
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,975.80 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184278900
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,000.75 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184278902
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,548.50 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184278904
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,254.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184278906
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,600.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184278908
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $108.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184278910
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184278912
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $924.75 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184278914
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 12/16/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220797059
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,322.70 12/15/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220797063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,866.21 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274773
Principal investigator 1 ABBVIE INC. $17,076.15 12/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529380
Principal investigator 1 Genentech, Inc. $11,427.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568841
Principal investigator 1 GlaxoSmithKline, LLC. $1,999.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192181746
Principal investigator 1 Hoffmann-La Roche Limited $1,604.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569472
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,222.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269269
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672036
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672038
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672040
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672042
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672044
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672046
Principal investigator 1 Genentech, Inc. $250.00 11/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567780
Principal investigator 1 Genentech, Inc. $1,250.00 11/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568098
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,672.67 11/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184264459
Principal investigator 1 Genentech, Inc. $5,683.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567740
Principal investigator 1 Hoffmann-La Roche Limited $10,943.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569156
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,810.14 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263531
Principal investigator 1 Hoffmann-La Roche Limited $27,618.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,753.70 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261251
Principal investigator 1 Genentech, Inc. $1,436.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567687
Principal investigator 1 Genentech, Inc. $7,967.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567804
Principal investigator 1 Genentech, Inc. $4,895.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568011
Principal investigator 1 Genentech, Inc. $5,226.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568027
Principal investigator 1 Genentech, Inc. $7,108.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568212
Principal investigator 1 Genentech, Inc. $4,049.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568274
Principal investigator 1 Genentech, Inc. $2,154.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568564
Principal investigator 1 Genentech, Inc. $6,072.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568690
Principal investigator 1 Hoffmann-La Roche Limited $4,000.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569018
Principal investigator 1 Hoffmann-La Roche Limited $31,464.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569309
Principal investigator 1 Hoffmann-La Roche Limited $12,320.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,970.14 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,645.32 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,548.50 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $969.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,594.10 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $344.25 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,194.50 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,586.60 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258649
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,699.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $342.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $160.65 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,849.50 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $432.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $228.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $700.65 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $924.75 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,740.77 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,760.91 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $673.38 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $673.38 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184259033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,118.69 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184259047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51,015.69 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184259123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,082.82 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184259175
Principal investigator 1 ABBVIE INC. $44,794.35 11/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522219
Principal investigator 1 GlaxoSmithKline, LLC. $141.00 11/03/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192181750
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672024
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672026
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672028
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672030
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672032
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672034
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,396.75 10/30/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220797061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $229,691.16 10/16/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250583
Principal investigator 1 ABBVIE INC. $36,547.20 10/09/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202515031
Principal investigator 1 GlaxoSmithKline, LLC. $53.00 10/02/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183856
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672012
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672014
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672016
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672018
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672020
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672022
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/24/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672010
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,238.60 09/18/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220797057
Principal investigator 1 GlaxoSmithKline, LLC. $76.00 09/08/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192147720
Principal investigator 1 ABBVIE INC. $52,064.10 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509808
Principal investigator 1 Genentech, Inc. $76.95 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567114
Principal investigator 1 Genentech, Inc. $843.75 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567117
Principal investigator 1 Genentech, Inc. $10,412.00 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567151
Principal investigator 1 Genentech, Inc. $588.15 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567168
Principal investigator 1 Genentech, Inc. $1,231.60 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567171
Principal investigator 1 Genentech, Inc. $55,056.00 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567355
Principal investigator 1 Genentech, Inc. $282.25 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,414.15 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,296.00 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235229
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $684.00 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235231
Principal investigator 1 GlaxoSmithKline, LLC. $5,017.90 09/03/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183847
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671972
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671974
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671976
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671978
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671980
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671998
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 08/26/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672006
Principal investigator 1 Boehringer Ingelheim International GmbH $22.62 08/26/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672008
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,202.17 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $864.00 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $456.00 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $861.30 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.00 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230591
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $69.00 08/21/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220797055
Principal investigator 1 Genentech, Inc. $6,735.00 08/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,414.15 08/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184228419
Principal investigator 1 ABBVIE INC. $14,349.15 08/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202502969
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,724.15 08/06/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220797053
Principal investigator 1 GlaxoSmithKline, LLC. $1,914.00 08/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192181771
Principal investigator 1 GlaxoSmithKline, LLC. $13,240.60 08/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192181741
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671962
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671964
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671966
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671968
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671970
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 08/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671992
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671996
Principal investigator 1 Novo Nordisk AS $219.60 07/31/2025 Non-covered Recipient Entity
ACCELLACARE
NN9535-4801 No dispute reported 06/30/2026 1213706737
Principal investigator 1 Novo Nordisk AS $219.60 07/31/2025 Non-covered Recipient Entity
ACCELLACARE
NN9535-4801 No dispute reported 06/30/2026 1213725240
Principal investigator 1 Novo Nordisk AS $219.60 07/31/2025 Non-covered Recipient Entity
ACCELLACARE
NN9535-4801 No dispute reported 06/30/2026 1213832390
Principal investigator 1 Novo Nordisk AS $219.60 07/31/2025 Non-covered Recipient Entity
ACCELLACARE
NN9535-4801 No dispute reported 06/30/2026 1213834089
Principal investigator 1 Novo Nordisk AS $219.60 07/31/2025 Non-covered Recipient Entity
ACCELLACARE
NN9535-4801 No dispute reported 06/30/2026 1213839098
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 07/28/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672000
Principal investigator 1 Boehringer Ingelheim International GmbH $1,022.00 07/28/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672002
Principal investigator 1 Boehringer Ingelheim International GmbH $34.80 07/28/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220672004
Principal investigator 1 GlaxoSmithKline, LLC. $6,445.30 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192147724
Principal investigator 1 Genentech, Inc. $15,814.00 07/22/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,784.43 07/22/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217931
Principal investigator 1 Novo Nordisk AS $6,154.32 07/21/2025 Non-covered Recipient Entity
ACCELLACARE
NN9535-4801 No dispute reported 06/30/2026 1213778470
Principal investigator 1 Genentech, Inc. $8,366.00 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,353.29 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214452
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,784.43 07/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212923
Principal investigator 1 ABBVIE INC. $29,008.80 07/02/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202496547
Principal investigator 1 Novo Nordisk AS $3,000.00 07/02/2025 Non-covered Recipient Entity
ACCELLACARE
NN9535-4801 No dispute reported 06/30/2026 1213808490
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671982
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671984
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671986
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671988
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671990
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671994
Principal investigator 1 Novo Nordisk AS $456.00 06/30/2025 Non-covered Recipient Entity
ACCELLACARE
NN9535-4801 No dispute reported 06/30/2026 1213703743
Principal investigator 1 Novo Nordisk AS $456.00 06/30/2025 Non-covered Recipient Entity
ACCELLACARE
NN9535-4801 No dispute reported 06/30/2026 1213716220
Principal investigator 1 Novo Nordisk AS $456.00 06/30/2025 Non-covered Recipient Entity
ACCELLACARE
NN9535-4801 No dispute reported 06/30/2026 1213729000
Principal investigator 1 Novo Nordisk AS $219.60 06/30/2025 Non-covered Recipient Entity
ACCELLACARE
NN9535-4801 No dispute reported 06/30/2026 1213758029
Principal investigator 1 Novo Nordisk AS $219.60 06/30/2025 Non-covered Recipient Entity
ACCELLACARE
NN9535-4801 No dispute reported 06/30/2026 1213759031
Principal investigator 1 Novo Nordisk AS $219.60 06/30/2025 Non-covered Recipient Entity
ACCELLACARE
NN9535-4801 No dispute reported 06/30/2026 1213775294
Principal investigator 1 Novo Nordisk AS $219.60 06/30/2025 Non-covered Recipient Entity
ACCELLACARE
NN9535-4801 No dispute reported 06/30/2026 1213789108
Principal investigator 1 Novo Nordisk AS $219.60 06/30/2025 Non-covered Recipient Entity
ACCELLACARE
NN9535-4801 No dispute reported 06/30/2026 1213801404
Principal investigator 1 Novo Nordisk AS $456.00 06/30/2025 Non-covered Recipient Entity
ACCELLACARE
NN9535-4801 No dispute reported 06/30/2026 1213836961
Principal investigator 1 Novo Nordisk AS $456.00 06/30/2025 Non-covered Recipient Entity
ACCELLACARE
NN9535-4801 No dispute reported 06/30/2026 1213838887
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,722.70 06/26/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220797051
Principal investigator 1 GlaxoSmithKline, LLC. $1,293.90 06/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192147727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,122.25 06/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209386
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,296.00 06/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209388
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,880.25 06/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209390
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $684.00 06/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209392
Principal investigator 1 F. Hoffmann-La Roche AG $2,234.60 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566446
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,568.86 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $399.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $756.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,774.25 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $456.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $864.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,699.00 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $456.00 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $864.00 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204317
Principal investigator 1 Amgen Inc. $104,153.31 06/04/2025 Non-covered Recipient Entity
ACELLACARE US INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight No dispute reported 06/30/2026 1246638813
Principal investigator 1 ABBVIE INC. $57,777.30 06/03/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202487889
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671942
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671944
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671946
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671948
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671950
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671952
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,837.57 05/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,512.71 05/22/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197865
Principal investigator 1 GlaxoSmithKline, LLC. $862.60 05/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183860
Principal investigator 1 GlaxoSmithKline, LLC. $53.00 05/16/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192181761
Principal investigator 1 F. Hoffmann-La Roche AG $10,108.00 05/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566384
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,245.94 05/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,806.47 05/08/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184193811
Principal investigator 1 ABBVIE INC. $30,581.55 05/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483579
Principal investigator 1 AstraZeneca Pharmaceuticals LP $509,188.14 05/02/2025 Non-covered Recipient Entity
ACCELLACARE
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity No dispute reported 06/30/2026 1185554236
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671930
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671932
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671934
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671936
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671938
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671940
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,400.00 05/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220797049
Principal investigator 1 F. Hoffmann-La Roche AG $6,048.00 04/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,726.44 04/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184190783
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 04/23/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671954
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 04/23/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671956
Principal investigator 1 Boehringer Ingelheim International GmbH $17.40 04/23/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671958
Principal investigator 1 Boehringer Ingelheim International GmbH $13.80 04/23/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671960
Principal investigator 1 GlaxoSmithKline, LLC. $5,779.80 04/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192181755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,459.67 04/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $456.00 04/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $864.00 04/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.31 04/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $76.95 04/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 04/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21,676.14 04/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184183400
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,847.69 04/08/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184182078
Principal investigator 1 ABBVIE INC. $10,939.05 04/03/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202470190
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671918
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671920
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671922
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671924
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671926
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671928
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,427.46 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180838
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,847.69 03/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184178884
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $611.00 03/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184178894
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $59,030.15 03/21/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220797047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,988.03 03/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174612
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,877.95 03/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170916
Principal investigator 1 ABBVIE INC. $38,577.60 03/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202461589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $912.00 03/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184157171
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $294.00 03/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184157173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,942.00 03/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184157175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 03/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184157177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.31 03/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184157179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,229.03 03/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184157181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,376.59 03/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156770
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671896
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671898
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671900
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671902
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671904
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671906
Principal investigator 1 Amgen Inc. $34,695.36 02/25/2025 Non-covered Recipient Entity
ACCELLACARE OF KNOXVILLE
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight No dispute reported 06/30/2026 1246638698
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 02/25/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671912
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 02/25/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671914
Principal investigator 1 Eli Lilly and Company $439.20 02/25/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187887506
Principal investigator 1 GlaxoSmithKline, LLC. $4,526.75 02/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192181758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,669.24 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154448
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $342.00 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154658
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,290.60 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154660
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154662
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,167.88 02/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153008
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $611.00 02/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153030
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $913.95 02/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153070
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $228.00 02/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153072
Principal investigator 1 ABBVIE INC. $44,786.25 02/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202447457
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671880
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671882
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671884
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671886
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671888
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671890
Principal investigator 1 Boehringer Ingelheim International GmbH $49.88 02/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671892
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 02/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671894
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,323.07 01/29/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149832
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 01/27/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671908
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 01/27/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671910
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,932.10 01/27/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220797045
Principal investigator 1 GlaxoSmithKline, LLC. $7,972.40 01/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183852
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,071.25 01/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149032
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,381.35 01/17/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220797043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,142.50 01/17/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148057
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 01/08/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220797041
Principal investigator 1 GlaxoSmithKline, LLC. $53.00 01/08/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183864
Principal investigator 1 Eli Lilly and Company $16,213.00 01/07/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187887246
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,071.25 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145706
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,569.98 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184146186
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671870
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671872
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671874
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671876
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671878
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Summit Medical Group South Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220671916